Claris Law Legal Blogging Community

Name:

E-mail:

Phone Number:

Zip Code:

Your Question:

Editor: Marc Jay Bern
Profession: Defective Medical Device Lawyer

Category: Medtronic News

European stroke patients were recently enrolled in Medtronic's clinical trial for Intrathecal Baclofen (ITB) therapy to treat spasticity.

While the study is only open to stroke patients, spasticity affects patients that suffer from other conditions also. ITB has already been approved for use in patients with spasticity issues associated with "multiple sclerosis, cerebral palsy, spinal cord injury, brain injury, and stroke failed to respond to oral medication."

Previous clinical trials have demonstrated the effectiveness of ITB in reducing spasticity in 89 percent of patients who received the treatment over six months. "The primary endpoint is the reduction of spasticity after six months of treatment with ITB Therapy and physical therapy compared to patients treated with one or more oral medications and physical therapy,"

[Read More]